Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
Want to see APRE full AI Analyst Report?
Total Valuation
Aprea Therapeutics has a market cap or net worth of $11.76M. The enterprise value is -$40.30M.
Market Cap$11.76M
Enterprise Value-$40.30M
Share Statistics
Aprea Therapeutics has 12,382,776 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,382,776
Owned by Insiders6.30%
Owned by Institutions15.36%
Financial Efficiency
Aprea Therapeutics’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -100.49%.
Return on Equity (ROE)-1.01
Return on Assets (ROA)-0.79
Return on Invested Capital (ROIC)-100.49%
Return on Capital Employed (ROCE)-1.00
Revenue Per Employee0.00
Profits Per Employee-1.57M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aprea Therapeutics is ―. Aprea Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio0.45
Price to Fair Value0.45
Price to FCF-0.43
Price to Operating Cash Flow-0.57
PEG Ratio0.02
Income Statement
In the last 12 months, Aprea Therapeutics had revenue of 0.00 and earned -12.60M in profits. Earnings per share was -1.93.
Revenue0.00
Gross Profit0.00
Operating Income-13.23M
Pretax Income-12.60M
Net Income-12.60M
EBITDA-13.21M
Earnings Per Share (EPS)-1.93
Cash Flow
In the last 12 months, operating cash flow was -12.22M and capital expenditures 0.00, giving a free cash flow of -12.22M billion.
Operating Cash Flow-12.22M
Free Cash Flow-12.22M
Free Cash Flow per Share-0.99
Dividends & Yields
Aprea Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.12
52-Week Price Change-47.09%
50-Day Moving Average0.83
200-Day Moving Average1.09
Relative Strength Index (RSI)56.49
Average Volume (3m)55.77K
Important Dates
Aprea Therapeutics upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Aprea Therapeutics as a current ratio of 5.63, with Debt / Equity ratio of 0.00%
Current Ratio5.63
Quick Ratio5.63
Debt to Market Cap0.00
Net Debt to EBITDA1.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aprea Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aprea Therapeutics EV to EBITDA ratio is 0.68, with an EV/FCF ratio of 0.70.
EV to Sales0.00
EV to EBITDA0.68
EV to Free Cash Flow0.70
EV to Operating Cash Flow0.70
Balance Sheet
Aprea Therapeutics has $46.47M in cash and marketable securities with $0.00 in debt, giving a net cash position of $46.47M billion.
Cash & Marketable Securities$46.47M
Total Debt$0.00
Net Cash$46.47M
Net Cash Per Share$3.75
Tangible Book Value Per Share$1.90
Margins
Gross margin is -1523.59%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-1523.59%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aprea Therapeutics is $4.07, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4.07
Price Target Upside306.67% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-90.40%
EPS Growth Forecast34.76%